Kazia Therapeutics (KZIA) vs PolyPid (PYPD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
PolyPid (PYPD) has outperformed Kazia Therapeutics (KZIA) over the past year, gaining 52.5% versus a gain of 24.4%. Over five years, PYPD leads with a -97.7% price change compared with -98.3% for KZIA. PolyPid is the larger company by market cap ($103.0 million vs $102.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KZIA | PYPD |
|---|---|---|
| Share price | $8.93 | $5.07 |
| Market cap | $102.04M | $102.98M |
| 1-day change | +1.25% | +3.47% |
| YTD return | +29.61% | +16.82% |
| 1-year return | +24.37% | +52.48% |
| 5-year return | -98.30% | -97.75% |
| EPS (TTM) | $-6.85 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.40 | $5.73 |
| 52-week low | $4.86 | $3.10 |
| Distance from 52-week high | -48.68% | -11.52% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +216.46% | +131.76% |
| Average volume | 262.75K | 175.46K |
| Shares outstanding | 11.43M | 20.31M |
| Employees | 6 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYPD has outperformed KZIA by 28.1 percentage points over the past year.
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Health Care · Medical/Dental Instruments · 69 employees
KZIA vs PYPD FAQ
Which is bigger, Kazia Therapeutics or PolyPid?
PolyPid (PYPD) is larger, with a market capitalization of $102.98M compared with $102.04M for Kazia Therapeutics (KZIA).
Which stock has performed better over the past year, KZIA or PYPD?
PYPD returned +52.48% over the past 12 months, compared with +24.37% for KZIA (price return, excluding dividends). Past performance does not predict future results.
Are Kazia Therapeutics and PolyPid in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Kazia Therapeutics and Medical/Dental Instruments for PolyPid.